

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8232125

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FILIP CALLEWAERT	04/30/2021
HILDE DE WINTER	02/08/2021
RECEIVING PARTY DATA	
Name:	ABLYNX N.V.
Street Address:	TECHNOLOGIEPARK 21
City:	ZWIJNAARDE
State/Country:	BELGIUM
Postal Code:	9052
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16967514
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6176468335
Email:	janet.oconnor@wolfgreenfield.com
Correspondent Name:	WOLF, GREENFIELD & SACKS, P.C.
Address Line 1:	600 ATLANTIC AVENUE
Address Line 4:	BOSTON, MASSACHUSETTS 02210
ATTORNEY DOCKET NUMBER:	A0848.70208US02
NAME OF SUBMITTER:	CURTIS R. POWELL
SIGNATURE:	/Curtis R. Powell/
DATE SIGNED:	10/20/2023
Total Attachments: 10	
source=A084870208US02-ASI-CRP#page1.tif	
source=A084870208US02-ASI-CRP#page2.tif	
source=A084870208US02-ASI-CRP#page3.tif	
source=A084870208US02-ASI-CRP#page4.tif	
source=A084870208US02-ASI-CRP#page5.tif	

source=A084870208US02-ASI-CRP#page6.tif
source=A084870208US02-ASI-CRP#page7.tif
source=A084870208US02-ASI-CRP#page8.tif
source=A084870208US02-ASI-CRP#page9.tif
source=A084870208US02-ASI-CRP#page10.tif

ASSIGNMENT

For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, the undersigned joint Inventors, each individually assign to **Ablynx N.V.**, a corporation formed under the laws of Belgium and having a principal place of business at Technologiepark 21, 9052 Zwijnaarde, Belgium, and its successors, transferees, and assignees (collectively the "Assignee"), all of our individual and joint rights, titles, and interests throughout the world in the subject matter (the "Subject Matter") disclosed or claimed in the patents and applications listed in Schedule A (the "Patents and Applications") and titled "**Methods of treating initial episode of TTP with immunoglobulin single variable domains**".

This Assignment, effective as of 06 February 2018 assigns (a) the Patents and Applications and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Patents, Applications, and Granted Rights") in every country or region, (b) the right to claim priority based on and the benefit of the filing date of any of the Patents, Applications, and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment.

We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee's name.

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment.

We will communicate to the Assignee (or at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter, will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and

documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

Signed at ZULTE, BELGIUM on this 30th day of April, 2021.
(City, State and Nation)

Signature:

Inventor's Name: CALLEWAERT, Filip

Mailing Address: c/o Ablynx N.V., Patent Department, Technologiepark 21, 9052
Zwijnaarde, Belgium

Witnessed by:

Signature

GRIET DE PESTEL

Printed Name

Signature

Dr. Christy Ratholli

Printed Name

Signed at _____ on this _____ day of _____, 2021.
(City, State and Nation)

Signature: _____
Inventor's Name: DE WINTER Hilde
Mailing Address: c/o Ablynx N.V., Patent Department, Technologiemark 21, 9052
Zwijnaarde, Belgium

Witnessed by:

Signature

Signature

Printed Name

Printed Name

ASSIGNMENT OF RIGHTS ACCEPTED BY Ablynx N.V.

Signed at Zwijnaarde on this 27 day of May, 2021.
(City, State and Nation)

By: 
Kristine De Sutter
Head of Sanofi R&D Belgium – Managing Director Ablynx

Kristine De Sutter
Site Head &
Managing Director Ablynx

SCHEDULE A

<u>App. No.</u>	<u>Country</u>	<u>Filing Date</u>
US 62/627,082	USA	6 February 2018
US 62/662,381	USA	25 April 2018
PCT/EP2019/052929	PCT INTERNATIONAL PROCEDURE	6 February 2019
P190100289	ARGENTINA	6 February 2019
108104485	TAIWAN	6 February 2019
200448	ALGERIA	6 February 2019
2019217584	AUSTRALIA	6 February 2019
BR112020015991-3	BRAZIL	6 February 2019
3,089,211	CANADA	6 February 2019
201980011292.X	CHINA	6 February 2019
1107/2020	EGYPT	6 February 2019
19705466.1	EUROPEAN PATENT	6 February 2019
276200	ISRAEL	6 February 2019
	JAPAN	6 February 2019
KW/P/2020/243	KUWAIT	6 February 2019
PI2020003735	MALAYSIA	6 February 2019
MX/a/2020/008294	MEXICO	6 February 2019
767451	NEW ZEALAND	6 February 2019
2020129228	RUSSIAN FEDERATION	6 February 2019
11202006902Q	SINGAPORE	6 February 2019
2020/04370	SOUTH AFRICA	6 February 2019
10-2020-7024118	SOUTH KOREA	6 February 2019
2001004242	THAILAND	6 February 2019
16/967,514	USA	6 February 2019

ASSIGNMENT

For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, the undersigned joint Inventors, each individually assign to **Ablynx N.V.**, a corporation formed under the laws of Belgium and having a principal place of business at Technologiepark 21, 9052 Zwijnaarde, Belgium, and its successors, transferees, and assignees (collectively the "Assignee"), all of our individual and joint rights, titles, and interests throughout the world in the subject matter (the "Subject Matter") disclosed or claimed in the patents and applications listed in Schedule A (the "Patents and Applications") and titled "**Methods of treating initial episode of TTP with immunoglobulin single variable domains**".

This Assignment, effective as of 06 February 2018 assigns (a) the Patents and Applications and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Patents, Applications, and Granted Rights") in every country or region, (b) the right to claim priority based on and the benefit of the filing date of any of the Patents, Applications, and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment.

We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee's name.

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment.

We will communicate to the Assignee (or at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter, will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

Signed at _____ on this _____ day of _____,
2/8/2021.
(City, State and Nation)

Signature: _____
Inventor's Name: CALLEWAERT Filip
Mailing Address: c/o Ablynx N.V., Patent Department, Technologiepark 21, 9052
Zwijnaarde, Belgium

Witnessed by:

Signature


Signature

Printed Name

Printed Name

Signed at Huizen, BELGIUM on this 8th day of February,
2/8/2021.
(City, State and Nation)


Assignment Page 2 of 4

Signature: 


Inventor's Name: DE WINTER Hilde

Mailing Address: c/o Ablynx N.V., Patent Department, Technologicpark 21, 9052
Zwijnaarde, Belgium

Witnessed by:

Signature 

DIRK ELEWAUT
Printed Name

Signature 

HILDE DE WINTER
Printed Name

ASSIGNMENT OF RIGHTS ACCEPTED BY Ablynx N.V.

Signed at Zwijnaarde on this 27 day of May 2021,
2/8/2021.
(City, State and Nation)



Assignment Page 3 of 4

Kristine De Sutter
Site Head &
Managing Director Ablynx

By: _____
Kristine De Sutter
Head of Sanofi R&D Belgium – Managing Director Ablynx

SCHEDULE A

<u>App. No.</u>	<u>Country</u>	<u>Filing Date</u>
US 62/627,082	USA	6 February 2018
US 62/662,381	USA	25 April 2018
PCT/EP2019/052929	PCT INTERNATIONAL	6 February 2019

Assignment Page 4 of 4

SCHEDULE A

<u>App. No.</u>	<u>Country</u>	<u>Filing Date</u>
US 62/627,082	USA	6 February 2018
US 62/662,381	USA	25 April 2018
PCT/EP2019/052929	PCT INTERNATIONAL PROCEDURE	6 February 2019
P190100289	ARGENTINA	6 February 2019
108104485	TAIWAN	6 February 2019
200448	ALGERIA	6 February 2019
2019217584	AUSTRALIA	6 February 2019
BR112020015991-3	BRAZIL	6 February 2019
3,089,211	CANADA	6 February 2019
201980011292.X	CHINA	6 February 2019
1107/2020	EGYPT	6 February 2019
19705466.1	EUROPEAN PATENT	6 February 2019
276200	ISRAEL	6 February 2019
	JAPAN	6 February 2019
KW/P/2020/243	KUWAIT	6 February 2019
PI2020003735	MALAYSIA	6 February 2019
MX/a/2020/008294	MEXICO	6 February 2019
767451	NEW ZEALAND	6 February 2019
2020129228	RUSSIAN FEDERATION	6 February 2019
11202006902Q	SINGAPORE	6 February 2019
2020/04370	SOUTH AFRICA	6 February 2019
10-2020-7024118	SOUTH KOREA	6 February 2019
2001004242	THAILAND	6 February 2019
16/967,514	USA	6 February 2019